Wall Street Zen Downgrades Elanco Animal Health (NYSE:ELAN) to Buy

by · The Cerbat Gem

Elanco Animal Health (NYSE:ELAN – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Sunday.

Several other brokerages also recently issued reports on ELAN. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Wednesday, November 19th. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, December 18th. Barclays started coverage on shares of Elanco Animal Health in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Stifel Nicolaus increased their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.78.

Check Out Our Latest Analysis on Elanco Animal Health

Elanco Animal Health Trading Up 1.6%

Shares of Elanco Animal Health stock opened at $23.85 on Friday. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $23.90. The stock has a market capitalization of $11.85 billion, a P/E ratio of 397.53, a price-to-earnings-growth ratio of 3.26 and a beta of 1.87. The company has a 50-day simple moving average of $22.29 and a 200 day simple moving average of $19.42. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the firm earned $0.13 earnings per share. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, CFO Robert M. Vanhimbergen bought 6,950 shares of the stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $21.64 per share, with a total value of $150,398.00. Following the acquisition, the chief financial officer owned 124,233 shares of the company’s stock, valued at approximately $2,688,402.12. The trade was a 5.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the purchase, the chief executive officer owned 167,000 shares in the company, valued at $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 43,450 shares of company stock worth $937,883 over the last quarter. 0.89% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SJS Investment Consulting Inc. raised its position in shares of Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares during the period. Huntington National Bank lifted its stake in Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares during the period. Farther Finance Advisors LLC increased its position in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after acquiring an additional 951 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its holdings in shares of Elanco Animal Health by 184.3% during the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after acquiring an additional 2,414 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Recommended Stories